📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Paushak Ltd Appoints Jain Parkash as Whole-time Director; COO Chintan Gosaliya Resigns
Paushak Limited has announced a leadership transition effective from the end of the 2025-26 fiscal year. Mr. Chintan Gosaliya will resign as Whole-time Director and COO on March 31, 2026, to pursue outside opportunities. To ensure continuity, the board has appointed Mr. Jain Parkash, the current Sr. VP of Operational Excellence, as a Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash brings over 30 years of specialized experience in specialty chemicals and pharma APIs to the role.
Key Highlights
Mr. Chintan Gosaliya to step down as Whole-time Director and COO on March 31, 2026.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term effective April 1, 2026.
New appointee Mr. Parkash has 30+ years of experience in Specialty Chemicals and Agro-Chemicals.
The appointment is an internal promotion and remains subject to shareholder approval via Special Resolution.
💼 Action for Investors
Investors should monitor the transition for any shifts in operational strategy, though the internal promotion of an experienced executive suggests a focus on continuity.
Paushak Ltd Appoints Jain Parkash as Whole-time Director; Chintan Gosaliya Resigns as COO
Paushak Limited has announced a leadership transition where Mr. Chintan Gosaliya will resign as Whole-time Director and COO effective March 31, 2026. To fill the vacancy, the Board has approved the appointment of Mr. Jain Parkash as an Additional and Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash is currently the Sr. Vice President of Operational Excellence and brings over 30 years of experience in Specialty Chemicals and Pharma API. This internal promotion suggests a focus on operational continuity and leveraging deep industry expertise.
Key Highlights
Mr. Chintan Gosaliya to step down as WTD and COO on March 31, 2026, to pursue outside opportunities.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term effective April 1, 2026.
Incoming director Mr. Jain Parkash has over 30 years of experience in Specialty Chemicals, Agro-Chemicals, and Pharma API.
The appointment is subject to shareholder approval through a Special Resolution.
Mr. Parkash also serves as a Non-Executive Director on the Board of Alembic Limited.
💼 Action for Investors
Investors should monitor the transition for any impact on operational efficiency, though the internal promotion of an experienced industry veteran is generally a stabilizing signal. No immediate action is required as the transition is scheduled for 2026.
Paushak Ltd Appoints Jain Parkash as Whole-time Director; Chintan Gosaliya Resigns as COO
Paushak Limited has announced a leadership transition where Mr. Chintan Gosaliya will resign as Whole-time Director and COO effective March 31, 2026. To ensure continuity, the board has appointed Mr. Jain Parkash, currently the Sr. VP of Operational Excellence, as a Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash brings over 30 years of extensive experience in Specialty Chemicals and Pharma APIs, which are critical sectors for the company. This internal promotion indicates a focus on maintaining operational stability and leveraging internal expertise for future growth.
Key Highlights
Mr. Chintan Gosaliya to resign as Whole-time Director and COO effective March 31, 2026.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term starting April 1, 2026.
New appointee Mr. Parkash has over 30 years of experience in Specialty Chemicals, Agro-Chemicals, and Pharma APIs.
The appointment is subject to shareholder approval through a Special Resolution.
Mr. Parkash also serves as a Non-Executive Director on the Board of Alembic Limited.
💼 Action for Investors
Investors should view this as a routine leadership transition; the internal promotion of an industry veteran suggests stability in operational management. No immediate action is required, but shareholders should look for the upcoming Special Resolution to formalize the appointment.
Paushak Ltd Q3 FY26 PAT Drops 59% YoY to ₹6.17 Cr; Revenue Declines to ₹48.8 Cr
Paushak Limited reported a weak performance for the quarter ended December 31, 2025, with Net Profit (PAT) falling 59.5% YoY to ₹6.17 crore from ₹15.26 crore. Revenue from operations saw a marginal decline YoY to ₹48.80 crore but a significant 17% drop on a sequential (QoQ) basis. Profitability was severely impacted by a sharp reduction in Other Income, which fell from ₹6.31 crore to just ₹0.97 crore YoY. Additionally, the company made a provision of ₹1.01 crore towards new Labour Code implementations.
Key Highlights
Revenue from Operations stood at ₹48.80 crore, down from ₹58.78 crore in the previous quarter (QoQ).
Net Profit (PAT) declined sharply to ₹6.17 crore compared to ₹15.26 crore in Q3 FY25.
Other Income dropped significantly to ₹0.97 crore from ₹6.31 crore in the corresponding quarter last year.
Restated EPS for the quarter fell to ₹2.50 from ₹6.19 YoY, accounting for the 3:1 bonus issue and stock split.
The company's equity shares were successfully listed on the National Stock Exchange (NSE) effective December 1, 2025.
💼 Action for Investors
Investors should exercise caution as the company faces both sequential and year-on-year declines in top-line and bottom-line performance. The significant drop in other income and the impact of new labour provisions warrant a closer look at the core operating margins in upcoming quarters.
Paushak Q3 PAT Drops 60% YoY to ₹6.17 Cr; Revenue Declines 17% QoQ
Paushak Limited reported a significant 59.6% YoY decline in Net Profit to ₹6.17 crore for Q3 FY26, down from ₹15.26 crore. Revenue from operations also faced pressure, falling 17% sequentially to ₹48.8 crore compared to the previous quarter. The company's margins were squeezed by rising employee costs, including a one-time provision of ₹1.01 crore for new labour codes. During the quarter, the company completed a 3:1 bonus issue and stock split, and successfully listed its shares on the NSE.
Key Highlights
Net Profit (PAT) plummeted 59.6% YoY to ₹6.17 crore from ₹15.26 crore in the previous year.
Revenue from operations stood at ₹48.8 crore, a 17% decline from ₹58.78 crore in Q2 FY26.
Employee benefit expenses increased to ₹10.90 crore, including a ₹1.01 crore provision for new Labour Codes.
Restated EPS for the quarter fell to ₹2.50 compared to ₹6.19 in the same period last year.
The company successfully listed on the National Stock Exchange (NSE) on December 1, 2025.
💼 Action for Investors
The sharp decline in profitability and sequential revenue drop are concerning; investors should wait for signs of margin recovery before increasing exposure. While the NSE listing improves liquidity, the underlying fundamental performance remains under pressure.
Paushak Ltd Commences Phased Production at New Rs 175 Cr Multi-Purpose Plant
Paushak Limited has initiated the phased commissioning of its new Multi-Purpose Plant for chemical derivatives and associated infrastructure. The project involves a significant investment of approximately Rs 175 crore, which is being funded through a combination of internal accruals and borrowings. This expansion is strategically designed to replace legacy manufacturing facilities and provide much-needed capacity enhancement, as existing facilities are currently optimally utilized. The full capacity from this expansion is expected to be added progressively over the next 12 months.
Key Highlights
Investment of approximately Rs 175 crore in a new Multi-Purpose Plant for derivatives
Commissioning process started in a phased manner to ensure smooth operational transition
Project rationale includes both replacement of legacy facilities and significant capacity enhancement
Proposed capacity to be fully integrated and added over the next 12 months
Financing structured through a mix of internal accruals and external borrowings
💼 Action for Investors
Investors should view this as a significant growth catalyst that addresses current capacity constraints. Monitor the quarterly revenue trajectory over the next year to track the successful ramp-up of this new facility.
Paushak Limited CRISIL Rating Reaffirmed; Bank Facilities Enhanced to Rs 145 Crore
CRISIL Ratings has reaffirmed Paushak Limited's long-term credit rating at 'CRISIL A/Stable' and assigned a short-term rating of 'CRISIL A1'. The total rated bank loan facilities have been significantly increased from Rs 40 crore to Rs 145 crore. This enhancement includes a new term loan of Rs 70 crore and expanded working capital facilities totaling Rs 75 crore. The reaffirmation of the 'Stable' outlook indicates the company's maintained creditworthiness despite the higher debt capacity.
Key Highlights
Long-term credit rating reaffirmed at 'CRISIL A/Stable' by CRISIL Ratings.
Short-term credit rating of 'CRISIL A1' assigned for working capital facilities.
Total bank loan facilities rated increased from Rs 40 crore to Rs 145 crore.
New facilities include a Rs 70 crore Term Loan and Rs 75 crore in total Working Capital limits.
The rating assignment covers both existing and proposed enhanced credit limits.
💼 Action for Investors
The reaffirmation of a strong credit rating alongside a significant increase in borrowing limits suggests the company is well-positioned for expansion. Investors should monitor the deployment of the new Rs 70 crore term loan for capital expenditure or growth initiatives.